A detailed history of Intellectus Partners, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Intellectus Partners, LLC holds 5,823 shares of BIIB stock, worth $1.33 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares
5,823
Previous 5,563 4.67%
Holding current value
$1.33 Million
Previous $1.44 Million 12.79%
% of portfolio
0.33%
Previous 0.42%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$212.02 - $267.71 $55,125 - $69,604
260 Added 4.67%
5,823 $1.26 Million
Q4 2023

Feb 05, 2024

SELL
$222.59 - $267.94 $11,129 - $13,397
-50 Reduced 0.89%
5,563 $1.44 Million
Q3 2023

Oct 25, 2023

BUY
$253.3 - $285.89 $3,292 - $3,716
13 Added 0.23%
5,613 $1.44 Million
Q2 2023

Jul 31, 2023

SELL
$275.25 - $318.06 $50,921 - $58,841
-185 Reduced 3.2%
5,600 $1.6 Million
Q1 2023

May 04, 2023

SELL
$256.56 - $292.34 $122,635 - $139,738
-478 Reduced 7.63%
5,785 $1.61 Million
Q4 2022

Feb 02, 2023

SELL
$252.44 - $306.72 $577,582 - $701,775
-2,288 Reduced 26.76%
6,263 $1.73 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $429,486 - $592,222
2,206 Added 34.77%
8,551 $2.28 Million
Q2 2022

Aug 12, 2022

BUY
$187.54 - $223.02 $601,065 - $714,779
3,205 Added 102.07%
6,345 $1.29 Million
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $217,022 - $273,436
1,120 Added 55.45%
3,140 $661,000
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $165,476 - $212,662
739 Added 57.69%
2,020 $484,000
Q3 2021

Nov 16, 2021

SELL
$282.99 - $369.05 $350,058 - $456,514
-1,237 Reduced 49.13%
1,281 $363,000
Q2 2021

Aug 13, 2021

BUY
$259.0 - $414.71 $29,526 - $47,276
114 Added 4.74%
2,518 $872,000
Q1 2021

May 17, 2021

BUY
$242.95 - $284.63 $17,735 - $20,777
73 Added 3.13%
2,404 $673,000
Q4 2020

Feb 18, 2021

BUY
$236.26 - $355.63 $78,202 - $117,713
331 Added 16.55%
2,331 $571,000
Q4 2020

Feb 12, 2021

SELL
$236.26 - $355.63 $31,895 - $48,010
-135 Reduced 6.32%
2,000 $571,000
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $106,437 - $122,895
-402 Reduced 15.85%
2,135 $606,000
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $5,949 - $7,878
-23 Reduced 0.9%
2,537 $679,000
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $7,796 - $9,890
-29 Reduced 1.12%
2,560 $810,000
Q4 2019

Jan 24, 2020

BUY
$220.06 - $304.07 $51,273 - $70,848
233 Added 9.89%
2,589 $768,000
Q3 2019

Oct 11, 2019

BUY
$217.44 - $243.88 $126,332 - $141,694
581 Added 32.73%
2,356 $549,000
Q2 2019

Aug 08, 2019

BUY
$219.29 - $241.72 $96,487 - $106,356
440 Added 32.96%
1,775 $415,000
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $14,952 - $23,388
69 Added 5.45%
1,335 $316,000
Q4 2018

Feb 14, 2019

BUY
$278.5 - $352.75 $12,811 - $16,226
46 Added 3.77%
1,266 $381,000
Q3 2018

Nov 15, 2018

SELL
$293.51 - $383.83 $76,899 - $100,563
-262 Reduced 17.68%
1,220 $431,000
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $10,815 - $12,890
42 Added 2.92%
1,482 $430,000
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $30,435 - $43,045
117 Added 8.84%
1,440 $394,000
Q4 2017

Feb 13, 2018

SELL
$307.64 - $344.58 $1,230 - $1,378
-4 Reduced 0.3%
1,323 $421,000
Q3 2017

Nov 14, 2017

SELL
$281.15 - $329.69 $23,054 - $27,034
-82 Reduced 5.82%
1,327 $416,000
Q2 2017

Aug 15, 2017

BUY
N/A
1,409
1,409 $382,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $33B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Intellectus Partners, LLC Portfolio

Follow Intellectus Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intellectus Partners, LLC with notifications on news.